Compare TWO & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWO | CRVS |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2009 | 2016 |
| Metric | TWO | CRVS |
|---|---|---|
| Price | $12.00 | $14.48 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | $12.56 | ★ $30.17 |
| AVG Volume (30 Days) | ★ 3.4M | 834.7K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 11.77% | N/A |
| EPS Growth | N/A | ★ 48.04 |
| EPS | ★ 0.18 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $66.61 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.84 | $4.70 |
| 52 Week High | $14.17 | $26.95 |
| Indicator | TWO | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 37.92 | 56.54 |
| Support Level | $10.89 | $14.24 |
| Resistance Level | $12.14 | $16.66 |
| Average True Range (ATR) | 0.04 | 0.69 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 6.67 | 96.61 |
Two Harbors Investment Corp is a real estate investment trust focused on investing in, financing, and managing residential mortgage-backed securities, residential mortgage loans, mortgage servicing rights, and commercial real estate. The majority of its investment portfolio is split between agency RMBS purchased from government-sponsored enterprises and nonagency RMBS. The company derives revenues mainly from its MSR and Agency RMBS portfolio, including servicing fee income, float income, and interest income, as well as mortgage loan origination activities established to support the MSR portfolio. Its investment portfolio is subject to market risks, mainly interest rate, basis, and prepayment risk. The majority of income is generated by available-for-sale securities.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.